WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Trevor Lyons
Patent Agent
Patents and Innovations
Boston
tlyons@wsgr.com

D202-791-8001

Download vCard
Open PDF

Dr. Trevor Lyons is a patent agent in the Boston office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. His technical expertise spans across a variety of fields including inorganic chemistry, polymer chemistry, physical chemistry, semiconductors, and nanomaterials for biological applications. 

Trevor received his Ph.D. in chemistry from Georgetown University where his doctoral research focused on the development and evaluation of novel organic-inorganic composite materials for use as magnetic resonance imaging (MRI) contrast agents. During this time, he worked closely with members of an interdisciplinary collaboration comprising medical researchers and physicists. Prior to his education at Georgetown, Trevor conducted research at Western Connecticut State University where he researched conductive metal organic frameworks. He has presented his research at several national conferences including the American Chemical Society national meetings.

Experience

Dr. Trevor Lyons is a patent agent in the Boston office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. His technical expertise spans across a variety of fields including inorganic chemistry, polymer chemistry, physical chemistry, semiconductors, and nanomaterials for biological applications. 

Trevor received his Ph.D. in chemistry from Georgetown University where his doctoral research focused on the development and evaluation of novel organic-inorganic composite materials for use as magnetic resonance imaging (MRI) contrast agents. During this time, he worked closely with members of an interdisciplinary collaboration comprising medical researchers and physicists. Prior to his education at Georgetown, Trevor conducted research at Western Connecticut State University where he researched conductive metal organic frameworks. He has presented his research at several national conferences including the American Chemical Society national meetings.

Education
  • Ph.D., Chemistry, Georgetown University, 2022
  • M.S., Chemistry, Georgetown University, 2020
  • B.A., Chemistry, Western Connecticut State University, 2017

    Minor in Mathematics

Admissions
  • U.S. Patent and Trademark Office
Credentials
Education
  • Ph.D., Chemistry, Georgetown University, 2022
  • M.S., Chemistry, Georgetown University, 2020
  • B.A., Chemistry, Western Connecticut State University, 2017

    Minor in Mathematics

Admissions
  • U.S. Patent and Trademark Office

Select Publications

  • Co-author, “Paramagnetic Mn8Fe8-co-Polystyrene Nanobeads as a Potential T1-T2Multimodal Magnetic Resonance Imaging Contrast Agent with In Vivo Studies,” 13(33) ACS Applied Materials & Interfaces 39042-39054, 2021
  • Co-author, “Paramagnetic Clusters of Mn3(O2CCH3)6(Bpy)2in Polyacrylamide Nanobeads as a New Design Approach to a T1-T2Multimodal Magnetic Resonance Imaging Contrast Agent,” 11(20) ACS Applied Materials & Interfaces 18153-18164, 2019
Insights

Select Publications

  • Co-author, “Paramagnetic Mn8Fe8-co-Polystyrene Nanobeads as a Potential T1-T2Multimodal Magnetic Resonance Imaging Contrast Agent with In Vivo Studies,” 13(33) ACS Applied Materials & Interfaces 39042-39054, 2021
  • Co-author, “Paramagnetic Clusters of Mn3(O2CCH3)6(Bpy)2in Polyacrylamide Nanobeads as a New Design Approach to a T1-T2Multimodal Magnetic Resonance Imaging Contrast Agent,” 11(20) ACS Applied Materials & Interfaces 18153-18164, 2019

Therapeutics and Drug Discovery

  • Drug conjugates
  • Drug delivery
  • Small molecules

Diagnostics and Medical Devices

  • Medical imaging

Chemistry and Material Science

  • Chemical synthesis
  • Chemistry
  • Materials chemistry
  • Nanochemistry
  • Organic chemistry
  • Organometallics
  • Polymers
Technical Fluency

Therapeutics and Drug Discovery

  • Drug conjugates
  • Drug delivery
  • Small molecules

Diagnostics and Medical Devices

  • Medical imaging

Chemistry and Material Science

  • Chemical synthesis
  • Chemistry
  • Materials chemistry
  • Nanochemistry
  • Organic chemistry
  • Organometallics
  • Polymers
Focus Areas
  • Patents and Innovations
Recent Insights
Client Highlights
Wilson Sonsini Advises on Patent Matters Related to Verona’s FDA Approval
On June 26, 2024, Verona Pharma announced that the U.S. Food and Drug Administration approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Ohtuvayre is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years. Wilson Sonsini Goodrich & Rosati advised Verona Pharma on patent matters.
Learn More
Client Highlights
Wilson Sonsini Advises Quince Therapeutics on Patent Matters Related to EryDel SpA Acquisition
On October 23, 2023, Quince Therapeutics, Inc., a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics, announced the successful completion of its acquisition of EryDel S.p.A., a privately-held, late-stage biotech company. Quince’s newly acquired Phase 3 lead asset, EryDex, targets a rare neurodegenerative disease, Ataxia-Telangiectasia (A-T). Currently, there are no approved treatments for A-T and the market represents a $1+ billion estimated peak sales opportunity globally. EryDex utilizes a highly differentiated and proprietary technology platform for autologous intracellular drug encapsulation (AIDE), which is designed to optimize the biodistribution of dexamethasone sodium phosphate (DSP; a pro-drug) by using an A-T patient’s own red blood cells to deliver the sustained therapeutic over a once monthly treatment period.
Learn More
View All
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.